What is Hyperion Biotechnology?
Founded in 1998 and headquartered in San Antonio, Texas, Hyperion Biotechnology operates as a multifaceted biomedical and clinical research enterprise. The firm distinguishes itself through a diverse service portfolio that spans program management, logistics, and specialized medical advisory services. As a certified HUB vendor and an 8(m) woman-owned entity, Hyperion provides essential support to the U.S. Department of Defense and various federal agencies. Their market position is defined by a commitment to streamlining management processes and enhancing operational efficiencies for government stakeholders, ensuring that mission-critical projects achieve successful outcomes through rigorous scientific and technological application.
How much funding has Hyperion Biotechnology raised?
Hyperion Biotechnology has raised a total of $680K across 2 funding rounds:
Debt
$350K
Debt
$330K
Debt (2020): $350K with participation from PPP
Debt (2021): $330K led by PPP
Key Investors in Hyperion Biotechnology
PPP
Public-Private Partnership
What's next for Hyperion Biotechnology?
With the recent influx of capital, Hyperion Biotechnology is well-positioned to expand its footprint in the federal contracting landscape. The company is expected to prioritize the enhancement of its clinical research infrastructure and the scaling of its advisory services to meet the evolving needs of the Department of Defense. By reinvesting in its core competencies—logistics, program management, and biomedical innovation—Hyperion aims to solidify its role as a primary contractor for complex, large-scale government initiatives. Future growth will likely focus on diversifying its client base while maintaining the high standards of compliance and operational excellence required for federal-level partnerships.
See full Hyperion Biotechnology company page
